Back to results
US 2025/0051461 A1Published application
Methods for the treatment of thyroid eye disease
AssigneeHorizon Therapeutics Ireland DAC
InventorsDavid Madden, Kathleen Gabriel, Guido Magni, Richard Woodward
Life of this patent
Estimating the term…
Abstract
The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
Claims27
A method of treating a subject with thyroid eye disease, comprising:
- reducing proptosis in the subject with thyroid eye disease by administering to the subject an antibody comprising a heavy chain comprising CDRH1, CDRH2, and CDRH3 and a light chain comprising CDRL1, CDRL2, and CDRL3, as set forth in SEQ ID NOs:
- 1-6, respectively, wherein the antibody specifically binds and inhibits insulin-like growth factor I receptor,
- wherein the antibody is administered at a dosage of about 5 mg/kg to about 10 mg/kg antibody as a first dose, and
- wherein the proptosis is reduced by at least 3 mm.
1 more element
A method of treating a subject with thyroid eye disease, comprising:
- reducing proptosis in the subject with thyroid eye disease by administering to the subject a course of intravenous infusions of an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 8, wherein the antibody specifically binds and inhibits insulin-like growth factor I receptor,
- wherein the course of intravenous infusions comprises an initial intravenous infusion of the antibody at a dosage of about 5 mg/kg to about 10 mg/kg and subsequent intravenous infusions of the antibody at a dosage of about 5 mg/kg to about 20 mg/kg, and
- wherein after administration of the course of intravenous infusions proptosis is reduced by at least 3 mm.
2 more elements
A method of reducing proptosis by at least 2 mm in a subject with thyroid eye disease (TED),
- comprising administering to the subject an effective amount of an antibody, comprising a heavy chain comprising CDR1, CDR2 and CDR3 and a light chain comprising CDR1, CDR2 and CDR3, as set forth in SEQ ID NOs:
- 1-6, respectively, wherein the antibody specifically binds and inhibits insulin-like growth factor I receptor (IGF-IR),
- wherein the antibody is administered at a dosage of about 5 mg/kg to about 10 mg/kg antibody as a first dose.
Dependencies are inferred from the claim text.